The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume

Table 1 Patient characteristics

Characteristics	PORT	Non-PORT	P-value
Characteristics	No. (%)	No. (%)	P-value
Patients (N)	70	287
Age (yr)			0.55
≤60	43 (61.4)	165 (57.5)
>60	27 (38.6)	122 (42.5)
Gender			0.03
Male	35 (50)	184 (64.1)
Female	35 (50)	103 (35.9)
Smoking history^*			0.004
Never/light	46 (65.7)	134 (46.7)
Current/heavy	24 (34.3)	153 (53.3)
Clinical N status			0.45
cN0,1	35 (50)	158 (55.1)
cN2	35 (50)	129 (44.9)
Pathologic T stage			0.05
pT1	15 (21.4)	65 (22.7)
pT2	53 (75.7)	186 (64.8)
pT3	2 (2.9)	36 (12.5)
Type of surgery			0.01
Lobectomy	67 (95.7)	244 (85.0)
Sleeve lobectomy	3 (4.3)	9 (3.1)
Pneumonectomy	0	34 (11.9)
Tumor location			0.13
RUL	26 (37.1)	73 (25.4)
RML	9 (12.9)	24 (8.4)
RLL	12 (17.1)	50 (17.4)
LUL	14 (20.0)	90 (31.4)
LLL	9 (12.9)	50 (17.4)
Histology			0.56
Adenocarcinoma	47 (67.2)	169 (58.9)
Squamous	15 (21.4)	85 (29.6)
Adenosquamous	6 (8.6)	22 (7.7)
Large cell	1 (1.4)	9 (3.1)
Pleomorphic	1 (1.4)	2 (0.7)
N of positive nodes			0.04
≤4	30 (42.9)	162 (56.4)
>4	40 (57.1)	125 (43.6)
LNR			0.002
≤20%	22 (31.4)	150 (52.3)
>20%	48 (68.6)	137 (47.7)
Involved N2 stations			0.32
Single	31 (44.3)	146 (50.9)
Multiple	39 (55.7)	141 (49.1)
Cycles of POCT			0.08
<4	12 (17.1)	78 (27.2)
≥4	58 (82.9)	209 (72.8)
Subsequent EGFR-TKI therapy			0.004
Yes	22 (31.4)	47 (16.4)
No/unknown	48 (68.6)	240 (83.6)

Note: *Smoking history was categorized as never/light ex-smokers (<100 cigarettes smoked in the lifetime or smoked ≤10 pack-years, having stopped for ≥15 years) or, the current/heavy ex-smokers.
Abbreviations: LNR = lymph node ratio (defined as the ratio of metastatic to examined lymph nodes), RUL = right upper lobe, RML = right middle lobe, RLL = right lower lobe, LUL = left upper lobe, LLL = left lower lobe, PORT = postoperative radiotherapy, POCT = postoperative chemotherapy, EGFR-TKI = epidermal growth factor receptor tyrosine kinase inhibitor.

ISSN: 1471-2407